Category: Pharma Industry

Health Centers File 340B Dispute Resolution Petitions Against Drug Manufacturers

In Federal, Judicial, Pharma Industry, RegulatoryJanuary 14, 2021

The National Association of Community Health Centers (NACHC) last night on its members’ behalf asked a new federal 340B program administrative dispute resolution (ADR) panel to order drug manufacturers Eli Lilly and Co., Sanofi, and AstraZeneca to lift all “qualifications, …

Lilly Asks Court to Shield it From “Crippling” 340B Sanctions

In Federal, Judicial, Pharma IndustryJanuary 14, 2021

Tom Mirga

340B program stakeholders are still digesting drug manufacturers AstraZeneca, Eli Lilly and Co., and Sanofi’s Jan. 12 lawsuits to block federal sanctions over their decisions to stop or impose conditions on 340B discounts on drugs dispensed by contract pharmacies. …

AstraZeneca, Lilly, and Sanofi Sue HHS to Block Requirement To Give 340B Discounts To Contract Pharmacies

In Federal, Judicial, Pharma Industry, RegulatoryJanuary 13, 2021

Tom Mirga

In a major escalation of the fight over 340B contract pharmacy, drug manufacturer AstraZeneca late yesterday asked a federal court to declare that it “is not required to offer 340B discounts to contract pharmacies.”

Please Login

…

340B Providers Blindsided by Bausch Health’s Decision to Drop AmerisourceBergen as Distributor

In Federal, Other Industry, Pharma Industry, RegulatoryJanuary 12, 2021

Tom Mirga

Drug manufacturer Bausch Health blindsided 340B covered entities on New Year’s Eve, announcing that starting the very next day, Jan. 1, more than 200 of its branded products and future branded products would no longer be available through distributor AmerisourceBergen …

Senate Democratic Chairs-in-Waiting Waste No Time Going to Bat for 340B Providers

In Federal, Legislative, Pharma Industry, RegulatoryJanuary 12, 2021

Tom Mirga

The incoming Democratic chairs of two key U.S. Senate committees want the federal agency in charge of the 340B program “to take immediate action to clarify that implementation of a rebate model by [drug] manufacturers would violate a material condition …

Trump Pardons Disgraced 340B Critic

In Federal, Judicial, Pharma IndustryDecember 23, 2020

Tom Mirga

Kalderos Expects its 340B Rebate Model Will Finally Lift Off During Q1 2021

In Federal, Other Industry, Pharma Industry, RegulatoryDecember 17, 2020

Tom Mirga

Drug manufacturer vendor Kalderos says it expects several companies to begin using its 340B Pay platform during the next three months.

Kalderos Expects its 340B Rebate Model

…

Category: Pharma Industry

Health Centers File 340B Dispute Resolution Petitions Against Drug Manufacturers

Lilly Asks Court to Shield it From “Crippling” 340B Sanctions

AstraZeneca, Lilly, and Sanofi Sue HHS to Block Requirement To Give 340B Discounts To Contract Pharmacies

Please Login

340B Providers Blindsided by Bausch Health’s Decision to Drop AmerisourceBergen as Distributor

Senate Democratic Chairs-in-Waiting Waste No Time Going to Bat for 340B Providers

Trump Pardons Disgraced 340B Critic

Kalderos Expects its 340B Rebate Model Will Finally Lift Off During Q1 2021

Kalderos Expects its 340B Rebate Model

The New York Times, Often a Public Policy Shaper, Runs Article on 340B Pricing Denials

Providers Are Pleased, PhRMA Isn’t, With Becerra and State AGs’ 340B Letter to Azar

SPONSORED BY

BREAKING: Hospitals Sue HHS Over Drug Companies’ Denials of 340B Pricing